Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

For example, 2024’s biopharma IPO market began promisingly with $3.6 billion in total funding in Q1 – the highest in several ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Blood centres cannot make cell therapies more accessible on their own. For decades they have partnered with hospitals to ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five years ...